Transcription of Press release Second quarter 2021
{{id}} {{{paragraph}}}
Example: quiz answers
Press release Second quarter 2021
Press release Second quarter 2021 Q2 Results summary Total and Adjusted results Quarterly performance YTD performance Financial information Issued: Wednesday, 28 July 2021, London, 1 Issued: Wednesday, 28 July 2021, London GSK delivers strong Q2 sales of billion, +6% AER, +15% CER Total EPS -39% AER, -28% CER; Adjusted EPS +46% AER +71% CER Highlights Sales growth driven by strong commercial execution and favourable prior year comparison Pharmaceuticals billion +3% AER, +12% CER with growth in New and Specialty products (+25% CER) including Respiratory +36% CER, Immuno-Inflammation +46% CER, Oncology +69% CER, total HIV +14% CER Vaccines billion +39% AER, +49% CER reflecting strong growth in Meningitis +46% CER, Established Vaccines +28% CER, Shingrix +1% CER with improved performance notably in the US and 258 million pandemic adjuvant sales. Continue to expect strong growth from Shingrix in H2 Consumer Healthcare billion -4% AER, +3% CER (+7% CER excluding divestments/brands under review) Effective cost control supports delivery of adjusted earnings per share growth Total Group operating margin Total EPS -39% AER, -28% CER Adjusted Group operating margin Adjusted EPS +46% AER, +71% CER (H1 -10% AER, +2% CER).
All expectations, guidance and targets regarding future performance and dividend payments should be read together with ‘Outlook, assumptions and cautionary statements’ on pages 68 and 69. If exchange rates were to hold at the closing rates on 30 June 2021 ($1.39/£1, €1.17/£1 and Yen 153/£1) for the rest of 2021, the
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: